Effect of high expression of type Ⅰ collagen α1 chain protein on the prognosis of triple negative breast cancer / 中华肿瘤杂志

Objective@#To investigate the expression of type Ⅰ collagen α1 chain protein (COL1A1) in triple negative breast cancer (TNBC), and its relationship with clinicopathological features and prognosis of TNBC.@*Methods@#A total of 148 TNBC specimens were collected from the Affiliated Cancer Hospital of Xinjiang Medical University from 2013 to 2015. The mRNA expression of COL1A1 was detected by fluorescence quantitative RT-PCR and the protein expression of COL1A1 was detected by Western blot. The expression of COL1A1 and α-smooth muscle actin (α-SMA) in TNBC were detected by immunohistochemistry. The relationship between the expression of COL1A1 and clinicopathological parameters and prognosis of TNBC patients was analyzed.@*Results@#The mRNA and protein expression of COL1A1 in MDA-MB-231 cells were 1.696±0.486 and 0.550±0.088, respectively, which were higher than those in MCF-10A cells (1.020±0.231 and 0.350±0.083, P=0.032, P=0.046). The mRNA and protein expression of COL1A1 in TNBC tissues were 1.632 ±0.598 and 0.733 ±0.068, respectively, which were higher than those in paracancerous tissues (1.041±0.316 and 0.612±0.016, P=0.003, P=0.039). The high expression rates of COL1A1 and α-SMA in TNBC tissues were 35.8% and 56.7% respectively, which were higher than those in paracancerous tissues (16.7% and 30.0%, P=0.041, P=0.037). The expression of COL1A1 was correlated with tumor size, TNM stage, lymph node metastasis, vascular invasion and α-SMA expression (all P<0.05). The median survival time in COL1A1 high expression group was 64 months, which was lower than that in low expression group (73 months, P<0.05). Multivariate analysis of Cox proportional hazard regression model showed that COL1A1 expression was an independent influencing factor for the survival of TNBC patients (HR=3.952, P=0.004).@*Conclusion@#The high expression of COL1A1 in TNBC is an independent prognostic factor of TNBC patients.

Progress of research on therapy and characteristics of gene and protein for triple-negative breast cancer / 国际外科学杂志

Triple-negative breast cancer,which lacks estrogen receptor,progesterone receptor,and human epidermal growth factor receptor 2,accounts for about 15％-20％ of breast cancers,and is the most aggressive breast cancer subtype.It displays poor prognosis from traditional therapies,therefore,there is an urgent need to find new treatments.This paper mainly describes the characteristics of protein and gene expression,such as PIM1,MYC,CDK4,TGF-β,TP53,MYOF,FOSB,MENA,and the latest research of therapeutic approaches of triplenegative breast cancer about PARP,PI3K/Akt/mTOR,EGFR,Hedgehog,Met,etc..